Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.
Ephrem
A
A
INSERM U430 and Université Pierre et Marie Curie (UPMC-Paris 6), Hôpital Broussais, 96 Rue Didot, 75014, Paris, France.
Misra
N
N
Hassan
G
G
Dasgupta
S
S
Delignat
S
S
Duong Van Huyen
J-P
JP
Chamat
S
S
Prost
F
F
Lacroix-Desmazes
S
S
Kavery
S V
SV
Kazatchkine
M D
MD
D000938:Antigen-Presenting Cells / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000276:immunology; D003165:Complement System Proteins / Q000502:physiology; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology; D009186:Myelin Sheath; D009500:Neutralization Tests; D013601:T-Lymphocytes / Q000276:immunology
D001323:Autoantibodies; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D003165:Complement System Proteins